利用各种生物物理模型评估立体定向体部位放射治疗（SBRT）对非小细胞肺癌（NSCLC）的治疗效果。由于此类模型参数基于临床经验进行经验性确定，因此体外和临床研究之间存在很大差距。在本研究中，考虑到细胞种群的异质性，我们通过一种建模方法进行了转化研究，以实现可能的联系。我们建立了细胞杀伤和肿瘤控制概率（TCP）模型，考虑到两种人口：后代和癌干细胞。模型参数基于A549和EBC-1细胞的体外存活数据确定。基于细胞参数，我们预测了TCP，并将其与收集自弘前大学医院的553名患者的相应临床数据进行了比较。使用一个称为综合微量剂量动力学（IMK）模型的多合一开发模型，我们成功地再现了急性照射后的体外存活率和各种分数方案下的3年TCP（6-10 Gy每分数）。从不考虑癌干细胞（CSCs）的常规预测中，该研究揭示了放射性耐受的CSCs在体外和临床结果之间的联系中发挥了关键作用。本研究提供了一种可能的普适生物物理模型，可以精确评估全球SBRT的估计。版权所有 © 2022 Elsevier B.V.。保留所有权利。

Curative effects of stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) have been evaluated using various biophysical models. Because such model parameters are empirically determined based on clinical experience, there is a large gap between in vitro and clinical studies. In this study, considering the heterogeneous cell population, we performed a translational study to realize the possible linkage based on a modeling approach.We modeled cell-killing and tumor control probability (TCP) considering two populations: progeny and cancer stem-like cells. The model parameters were determined from in vitro survival data of A549 and EBC-1 cells. Based on the cellular parameters, we predicted TCP and compared it with the corresponding clinical data from 553 patients collected at Hirosaki University Hospital.Using an all-in-one developed model, the so-called integrated microdosimetric-kinetic (IMK) model, we successfully reproduced both in vitro survival after acute irradiation and the 3-year TCP with various fractionation schemes (6-10 Gy per fraction). From the conventional prediction without considering cancer stem cells (CSCs), this study revealed that radioresistant CSCs play a key role in the linkage between in vitro and clinical outcomes.This modeling study provides a possible generalized biophysical model that enables precise estimation of SBRT worldwide.Copyright © 2022 Elsevier B.V. All rights reserved.